GeoVax Labs, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; balance-sheet figures are compared with December 31, 2019. GeoVax is a clinical-stage vaccine and immunotherapy developer using its MVA-VLP platform. It reported no product sales; revenue came from government grants and research collaborations.
Financial results and liquidity
- Revenue: $715,977, up 97% from $364,232 in Q1 2019. This comprised $654,021 in government grant revenue and $61,956 in collaboration revenue.
- Expenses and loss: R&D expense was $808,936, up 46%; G&A was $502,345, down slightly as reported. Excluding stock-based compensation, G&A rose 35% to $496,345, primarily due to legal and patent costs. Operating loss was $595,304 versus $701,550; net loss was $595,694 versus $701,454.
- Margins: The filing does not present a gross margin; the business is pre-product-revenue and grant-funded. Operating expenses exceeded revenue by $595,304.
- Cash flow: Operating cash use was $358,620, compared with $317,361 in Q1 2019. Financing provided $297,086, including $300,000 from preferred stock, partly offset by $2,914 of note repayments. Cash declined $61,534 during the quarter to $221,807.
- Balance sheet: Total assets were $830,833; current liabilities were $2,670,302 and total liabilities were $2,695,083. The company reported a $1,860,081 working-capital deficit and $1,864,250 stockholders’ deficiency. Note payable totaled $36,829, including $12,048 current.
- Other obligations: Accrued management salaries and director fees totaled $1,855,717 and were being deferred. The company disclosed approximately $539,000 in unrecorded vendor and subcontractor commitments expected to be reimbursed under existing grants. The office/lab lease runs through 2022 but may be terminated by either party on 90 days’ notice.
Material changes and capital structure
- Revenue increased with higher grant activity, particularly the Lassa fever U.S. Army grant; R&D spending also rose with grant-related work.
- During Q1, holders converted Series H and I preferred shares into 13,481,349 common shares. The company also issued 10,417 common shares for services. A one-for-2,000 reverse split took effect January 21, 2020; share and per-share data were retrospectively adjusted. Reported loss per share was $(0.13), compared with $(2,851.44) in Q1 2019, alongside a major change in weighted-average shares, so the per-share comparison should be interpreted cautiously.
- The company sold $300,000 of Series J preferred stock. Its conversion price is the lower of $2.00 per common share or 80% of the applicable 10-day volume-weighted average price, with price-adjustment provisions that may increase dilution.
Outlook, risks, and unusual items
- Management said available cash, government grants, and collaboration funding were expected to support planned operations into the third quarter of 2020. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond that point; management was seeking grants, collaborations, and equity financing, but said its plans did not alleviate the substantial doubt. Funding may not be available, and programs or expenses could be delayed, scaled back, or eliminated.
- GeoVax expected approximately $606,944 of approved grant funds to be available for 2020 use and approximately $307,000 of upcoming billable collaboration fees. It expects no product revenue for at least several years and anticipates continued losses and substantial R&D needs.
- Programs include preventive candidates for COVID-19, HIV, Zika, hemorrhagic fever viruses, and malaria, and therapeutic candidates for hepatitis B and cancers. Management said planned HIV clinical efforts could be delayed by the COVID-19 pandemic. The filing provides no forward cost or completion estimates for research programs.
- After quarter-end, GeoVax received a $170,200 Paycheck Protection Program loan on April 17, 2020, at 1% interest, due April 17, 2022. The company may apply for forgiveness of eligible amounts; forgiveness was not assured in the filing.
- Other risks include clinical and regulatory uncertainty, dependence on external funding and grant reimbursements, potential dilution, and competition. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether the company obtained sufficient financing after its stated Q3 2020 cash runway, and how that affected the going-concern risk.
- Actual grant and collaboration cash collections, including timing of receivables and reimbursement of the approximately $539,000 in commitments.
- Whether the PPP loan, or any portion of it, qualified for forgiveness and the resulting repayment obligations.
- Potential dilution from preferred-stock conversion terms, warrants, and other equity financing, alongside the effect of the reverse split on historical per-share comparisons.
- Whether COVID-19 disruptions changed clinical-trial timing, funding, or the company’s vaccine-development priorities.